Regeneron Pharmaceuticals, Inc.
—Price / book
Market cap
—
Tangible equity (USD)
—
Price / tangible book
—
Price / book
—
Net income / ending equity
14.4%
Net income / ending assets
11.1%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: REGN stock price vs JPM: inconclusive — current versus $667.62 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at JPM's multiple
Implied fair value · at REGN's multiple
Needs REGN P/E.
Close Dec 31, 2025
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency edge
Lower is better
Statements
Reported bank earnings and balances, with each company’s reporting period shown.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity (USD)
—
Price / tangible book
—
Price / book
—
Net income / ending equity
14.4%
Net income / ending assets
11.1%
Efficiency ratio
—
Price / tangible book
Market cap
$855.69B
Tangible equity (USD)
$307.11B
Price / tangible book
2.79x
Price / book
2.36x
Net income / ending equity
15.7%
Net income / ending assets
1.3%
Efficiency ratio
52.4%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REGENERON PHARMACEUTICALS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
JPMORGAN CHASE & CO · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
REGN vs AMGN
PFIZER INC
REGN vs PFE
BRISTOL MYERS SQUIBB CO
REGN vs BMY
BIOGEN INC.
REGN vs BIIB
GILEAD SCIENCES, INC.
REGN vs GILD
Seagate Technology Holdings plc
REGN vs STX
Bank of America Corporation
REGN vs BAC
Citigroup Inc.
REGN vs C
Wells Fargo & Company
REGN vs WFC
The Goldman Sachs Group, Inc.
REGN vs GS
Morgan Stanley
REGN vs MS
PNC FINANCIAL SERVICES GROUP, INC.
REGN vs PNC
US BANCORP \DE\
REGN vs USB
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.